Auspherix’s compounds – advantages for treating serious, potentially life-threatening infections
Auspherix’s new class of antibiotics are differentiated from current standard-of-care and last line antibiotics by their chemical class and distinct antibacterial profile.
Profile of Auspherix’s organogold compounds:
- Potent and broad spectrum activity against Gram-positive and Gram-negative bacteria including the ESKAPE pathogens.
- Retain activity against serious and potentially life-threatening multi-drug resistant (MDR) pathogens, including those deemed as a priority by the WHO. Auspherix’s antibacterials have shown activity against all pathogens listed in its report as ‘Critical’ threats: Acinetobacter, Pseudomonas and various Enterobacteriaceae
- Rapid bactericidal (killing rather than growth inhibition) activity against Gram-negative bacteria e.g. E coli.
- Activity against bacteria in different growth states i.e. planktonic (single) cells, biofilms and persister cells.
- Show low propensity for the emergence of resistance.
Furthermore, preliminary data implies that Auspherix’s molecules can be designed so that they can distribute preferentially to different body sites giving the potential to target specific organs or sites of infection.
Auspherix is building a pipeline of novel antibacterials with an initial focus on treating complicated urinary tract infections (cUTI).
The Company’s pipeline comprises three series of structurally distinct, organogold small molecules currently in lead optimisation.
We anticipate that a development candidate molecule from one of the current lead series will have progressed into clinical studies by early 2019.